Allosteric integrase inhibitor potency is determined through the inhibition of HIV-1 particle maturation
10.1073/pnas.1300703110
Crossref journal-article
Proceedings of the National Academy of Sciences
Proceedings of the National Academy of Sciences (341)
Abstract

Integration is essential for HIV-1 replication, and the viral integrase (IN) protein is an important therapeutic target. Allosteric IN inhibitors (ALLINIs) that engage the IN dimer interface at the binding site for the host protein lens epithelium-derived growth factor (LEDGF)/transcriptional coactivator p75 are an emerging class of small molecule antagonists. Consistent with the inhibition of a multivalent drug target, ALLINIs display steep antiviral dose–response curves ex vivo. ALLINIs multimerize IN protein and concordantly block its assembly with viral DNA in vitro, indicating that the disruption of two integration-associated functions, IN catalysis and the IN-LEDGF/p75 interaction, determines the multimode mechanism of ALLINI action. We now demonstrate that ALLINI potency is unexpectedly accounted for during the late phase of HIV-1 replication. The compounds promote virion IN multimerization and, reminiscent of class II IN mutations, block the formation of the electron-dense viral core and inhibit reverse transcription and integration in subsequently infected target cells. Mature virions are recalcitrant to ALLINI treatment, and compound potency during virus production is independent of the level of LEDGF/p75 expression. We conclude that cooperative multimerization of IN by ALLINIs together with the inability for LEDGF/p75 to effectively engage the virus during its egress from cells underscores the multimodal mechanism of ALLINI action. Our results highlight the versatile nature of allosteric inhibitors to primarily inhibit viral replication at a step that is distinct from the catalytic requirement for the target enzyme. The vulnerability of IN to small molecules during the late phase of HIV-1 replication unveils a pharmacological Achilles’ heel for exploitation in clinical ALLINI development.

Bibliography

Jurado, K. A., Wang, H., Slaughter, A., Feng, L., Kessl, J. J., Koh, Y., Wang, W., Ballandras-Colas, A., Patel, P. A., Fuchs, J. R., Kvaratskhelia, M., & Engelman, A. (2013). Allosteric integrase inhibitor potency is determined through the inhibition of HIV-1 particle maturation. Proceedings of the National Academy of Sciences, 110(21), 8690–8695.

Authors 12
  1. Kellie A. Jurado (first)
  2. Hao Wang (additional)
  3. Alison Slaughter (additional)
  4. Lei Feng (additional)
  5. Jacques J. Kessl (additional)
  6. Yasuhiro Koh (additional)
  7. Weifeng Wang (additional)
  8. Allison Ballandras-Colas (additional)
  9. Pratiq A. Patel (additional)
  10. James R. Fuchs (additional)
  11. Mamuka Kvaratskhelia (additional)
  12. Alan Engelman (additional)
References 50 Referenced 188
  1. A Engelman, P Cherepanov, The structural biology of HIV-1: Mechanistic and therapeutic insights. Nat Rev Microbiol 10, 279–290 (2012). (10.1038/nrmicro2747) / Nat Rev Microbiol / The structural biology of HIV-1: Mechanistic and therapeutic insights by Engelman A (2012)
  2. V Summa, et al., Discovery of raltegravir, a potent, selective orally bioavailable HIV-integrase inhibitor for the treatment of HIV-AIDS infection. J Med Chem 51, 5843–5855 (2008). (10.1021/jm800245z) / J Med Chem / Discovery of raltegravir, a potent, selective orally bioavailable HIV-integrase inhibitor for the treatment of HIV-AIDS infection by Summa V (2008)
  3. PK Quashie, T Mesplède, MA Wainberg, Evolution of HIV integrase resistance mutations. Curr Opin Infect Dis 26, 43–49 (2013). (10.1097/QCO.0b013e32835ba81c) / Curr Opin Infect Dis / Evolution of HIV integrase resistance mutations by Quashie PK (2013)
  4. S Hare, SS Gupta, E Valkov, A Engelman, P Cherepanov, Retroviral intasome assembly and inhibition of DNA strand transfer. Nature 464, 232–236 (2010). (10.1038/nature08784) / Nature / Retroviral intasome assembly and inhibition of DNA strand transfer by Hare S (2010)
  5. PK Quashie, RD Sloan, MA Wainberg, Novel therapeutic strategies targeting HIV integrase. BMC Med 10, 34 (2012). (10.1186/1741-7015-10-34) / BMC Med / Novel therapeutic strategies targeting HIV integrase by Quashie PK (2012)
  6. AR Schröder, et al., HIV-1 integration in the human genome favors active genes and local hotspots. Cell 110, 521–529 (2002). (10.1016/S0092-8674(02)00864-4) / Cell / HIV-1 integration in the human genome favors active genes and local hotspots by Schröder AR (2002)
  7. A Engelman, P Cherepanov, The lentiviral integrase binding protein LEDGF/p75 and HIV-1 replication. PLoS Pathog 4, e1000046 (2008). (10.1371/journal.ppat.1000046) / PLoS Pathog / The lentiviral integrase binding protein LEDGF/p75 and HIV-1 replication by Engelman A (2008)
  8. EM Poeschla, Integrase, LEDGF/p75 and HIV replication. Cell Mol Life Sci 65, 1403–1424 (2008). (10.1007/s00018-008-7540-5) / Cell Mol Life Sci / Integrase, LEDGF/p75 and HIV replication by Poeschla EM (2008)
  9. P Cherepanov, E Devroe, PA Silver, A Engelman, Identification of an evolutionarily conserved domain in human lens epithelium-derived growth factor/transcriptional co-activator p75 (LEDGF/p75) that binds HIV-1 integrase. J Biol Chem 279, 48883–48892 (2004). (10.1074/jbc.M406307200) / J Biol Chem / Identification of an evolutionarily conserved domain in human lens epithelium-derived growth factor/transcriptional co-activator p75 (LEDGF/p75) that binds HIV-1 integrase by Cherepanov P (2004)
  10. P Cherepanov, LEDGF/p75 interacts with divergent lentiviral integrases and modulates their enzymatic activity in vitro. Nucleic Acids Res 35, 113–124 (2007). (10.1093/nar/gkl885) / Nucleic Acids Res / LEDGF/p75 interacts with divergent lentiviral integrases and modulates their enzymatic activity in vitro by Cherepanov P (2007)
  11. P Cherepanov, ALB Ambrosio, S Rahman, T Ellenberger, A Engelman, Structural basis for the recognition between HIV-1 integrase and transcriptional coactivator p75. Proc Natl Acad Sci USA 102, 17308–17313 (2005). (10.1073/pnas.0506924102) / Proc Natl Acad Sci USA / Structural basis for the recognition between HIV-1 integrase and transcriptional coactivator p75 by Cherepanov P (2005)
  12. CJ McKee, et al., Dynamic modulation of HIV-1 integrase structure and function by cellular lens epithelium-derived growth factor (LEDGF) protein. J Biol Chem 283, 31802–31812 (2008). (10.1074/jbc.M805843200) / J Biol Chem / Dynamic modulation of HIV-1 integrase structure and function by cellular lens epithelium-derived growth factor (LEDGF) protein by McKee CJ (2008)
  13. JJ Kessl, et al., FRET analysis reveals distinct conformations of IN tetramers in the presence of viral DNA or LEDGF/p75. Nucleic Acids Res 39, 9009–9022 (2011). (10.1093/nar/gkr581) / Nucleic Acids Res / FRET analysis reveals distinct conformations of IN tetramers in the presence of viral DNA or LEDGF/p75 by Kessl JJ (2011)
  14. JJ Kessl, et al., Multimode, cooperative mechanism of action of allosteric HIV-1 integrase inhibitors. J Biol Chem 287, 16801–16811 (2012). (10.1074/jbc.M112.354373) / J Biol Chem / Multimode, cooperative mechanism of action of allosteric HIV-1 integrase inhibitors by Kessl JJ (2012)
  15. F Christ, et al., Small-molecule inhibitors of the LEDGF/p75 binding site of integrase block HIV replication and modulate integrase multimerization. Antimicrob Agents Chemother 56, 4365–4374 (2012). (10.1128/AAC.00717-12) / Antimicrob Agents Chemother / Small-molecule inhibitors of the LEDGF/p75 binding site of integrase block HIV replication and modulate integrase multimerization by Christ F (2012)
  16. M Tsiang, et al., New class of HIV-1 integrase (IN) inhibitors with a dual mode of action. J Biol Chem 287, 21189–21203 (2012). (10.1074/jbc.M112.347534) / J Biol Chem / New class of HIV-1 integrase (IN) inhibitors with a dual mode of action by Tsiang M (2012)
  17. H Wang, et al., HRP2 determines the efficiency and specificity of HIV-1 integration in LEDGF/p75 knockout cells but does not contribute to the antiviral activity of a potent LEDGF/p75-binding site integrase inhibitor. Nucleic Acids Res 40, 11518–11530 (2012). (10.1093/nar/gks913) / Nucleic Acids Res / HRP2 determines the efficiency and specificity of HIV-1 integration in LEDGF/p75 knockout cells but does not contribute to the antiviral activity of a potent LEDGF/p75-binding site integrase inhibitor by Wang H (2012)
  18. L Shen, et al., Dose-response curve slope sets class-specific limits on inhibitory potential of anti-HIV drugs. Nat Med 14, 762–766 (2008). (10.1038/nm1777) / Nat Med / Dose-response curve slope sets class-specific limits on inhibitory potential of anti-HIV drugs by Shen L (2008)
  19. A Engelman, In vivo analysis of retroviral integrase structure and function. Adv Virus Res 52, 411–426 (1999). (10.1016/S0065-3527(08)60309-7) / Adv Virus Res / In vivo analysis of retroviral integrase structure and function by Engelman A (1999)
  20. A Limón, et al., Nuclear localization of human immunodeficiency virus type 1 preintegration complexes (PICs): V165A and R166A are pleiotropic integrase mutants primarily defective for integration, not PIC nuclear import. J Virol 76, 10598–10607 (2002). (10.1128/JVI.76.21.10598-10607.2002) / J Virol / Nuclear localization of human immunodeficiency virus type 1 preintegration complexes (PICs): V165A and R166A are pleiotropic integrase mutants primarily defective for integration, not PIC nuclear import by Limón A (2002)
  21. A Engelman, G Englund, JM Orenstein, MA Martin, R Craigie, Multiple effects of mutations in human immunodeficiency virus type 1 integrase on viral replication. J Virol 69, 2729–2736 (1995). (10.1128/jvi.69.5.2729-2736.1995) / J Virol / Multiple effects of mutations in human immunodeficiency virus type 1 integrase on viral replication by Engelman A (1995)
  22. RH Kutner, XY Zhang, J Reiser, Production, concentration and titration of pseudotyped HIV-1-based lentiviral vectors. Nat Protoc 4, 495–505 (2009). (10.1038/nprot.2009.22) / Nat Protoc / Production, concentration and titration of pseudotyped HIV-1-based lentiviral vectors by Kutner RH (2009)
  23. SL Butler, MS Hansen, FD Bushman, A quantitative assay for HIV DNA integration in vivo. Nat Med 7, 631–634 (2001). (10.1038/87979) / Nat Med / A quantitative assay for HIV DNA integration in vivo by Butler SL (2001)
  24. L Li, et al., Role of the non-homologous DNA end joining pathway in the early steps of retroviral infection. EMBO J 20, 3272–3281 (2001). (10.1093/emboj/20.12.3272) / EMBO J / Role of the non-homologous DNA end joining pathway in the early steps of retroviral infection by Li L (2001)
  25. DJ Hazuda, et al., Inhibitors of strand transfer that prevent integration and inhibit HIV-1 replication in cells. Science 287, 646–650 (2000). (10.1126/science.287.5453.646) / Science / Inhibitors of strand transfer that prevent integration and inhibit HIV-1 replication in cells by Hazuda DJ (2000)
  26. F Christ, et al., Rational design of small-molecule inhibitors of the LEDGF/p75-integrase interaction and HIV replication. Nat Chem Biol 6, 442–448 (2010). (10.1038/nchembio.370) / Nat Chem Biol / Rational design of small-molecule inhibitors of the LEDGF/p75-integrase interaction and HIV replication by Christ F (2010)
  27. R Lu, et al., Class II integrase mutants with changes in putative nuclear localization signals are primarily blocked at a postnuclear entry step of human immunodeficiency virus type 1 replication. J Virol 78, 12735–12746 (2004). (10.1128/JVI.78.23.12735-12746.2004) / J Virol / Class II integrase mutants with changes in putative nuclear localization signals are primarily blocked at a postnuclear entry step of human immunodeficiency virus type 1 replication by Lu R (2004)
  28. WI Sundquist, H-G Kräusslich, HIV-1 assembly, budding, and maturation. Cold Spring Harb Perspect Med 2, a006924 (2012). (10.1101/cshperspect.a006924) / Cold Spring Harb Perspect Med / HIV-1 assembly, budding, and maturation by Sundquist WI (2012)
  29. CW Fenwick, et al., Resistance studies with HIV-1 non-catalytic site integrase inhibitors. Antivir Ther 16, A9 (2011). / Antivir Ther / Resistance studies with HIV-1 non-catalytic site integrase inhibitors by Fenwick CW (2011)
  30. E Yung, et al., Inhibition of HIV-1 virion production by a transdominant mutant of integrase interactor 1. Nat Med 7, 920–926 (2001). (10.1038/90959) / Nat Med / Inhibition of HIV-1 virion production by a transdominant mutant of integrase interactor 1 by Yung E (2001)
  31. D Motakis, MA Parniak, A tight-binding mode of inhibition is essential for anti-human immunodeficiency virus type 1 virucidal activity of nonnucleoside reverse transcriptase inhibitors. Antimicrob Agents Chemother 46, 1851–1856 (2002). (10.1128/AAC.46.6.1851-1856.2002) / Antimicrob Agents Chemother / A tight-binding mode of inhibition is essential for anti-human immunodeficiency virus type 1 virucidal activity of nonnucleoside reverse transcriptase inhibitors by Motakis D (2002)
  32. M Llano, et al., LEDGF/p75 determines cellular trafficking of diverse lentiviral but not murine oncoretroviral integrase proteins and is a component of functional lentiviral preintegration complexes. J Virol 78, 9524–9537 (2004). (10.1128/JVI.78.17.9524-9537.2004) / J Virol / LEDGF/p75 determines cellular trafficking of diverse lentiviral but not murine oncoretroviral integrase proteins and is a component of functional lentiviral preintegration complexes by Llano M (2004)
  33. M Li, M Mizuuchi, TR Burke, R Craigie, Retroviral DNA integration: Reaction pathway and critical intermediates. EMBO J 25, 1295–1304 (2006). (10.1038/sj.emboj.7601005) / EMBO J / Retroviral DNA integration: Reaction pathway and critical intermediates by Li M (2006)
  34. D Esposito, R Craigie, HIV integrase structure and function. Adv Virus Res 52, 319–333 (1999). (10.1016/S0065-3527(08)60304-8) / Adv Virus Res / HIV integrase structure and function by Esposito D (1999)
  35. C Petit, O Schwartz, F Mammano, Oligomerization within virions and subcellular localization of human immunodeficiency virus type 1 integrase. J Virol 73, 5079–5088 (1999). (10.1128/JVI.73.6.5079-5088.1999) / J Virol / Oligomerization within virions and subcellular localization of human immunodeficiency virus type 1 integrase by Petit C (1999)
  36. A Figueiredo, et al., Potent nonnucleoside reverse transcriptase inhibitors target HIV-1 Gag-Pol. PLoS Pathog 2, e119 (2006). (10.1371/journal.ppat.0020119) / PLoS Pathog / Potent nonnucleoside reverse transcriptase inhibitors target HIV-1 Gag-Pol by Figueiredo A (2006)
  37. A Mousnier, H Leh, J-F Mouscadet, C Dargemont, Nuclear import of HIV-1 integrase is inhibited in vitro by styrylquinoline derivatives. Mol Pharmacol 66, 783–788 (2004). (10.1124/mol.104.001735) / Mol Pharmacol / Nuclear import of HIV-1 integrase is inhibited in vitro by styrylquinoline derivatives by Mousnier A (2004)
  38. S Bonnenfant, et al., Styrylquinolines, integrase inhibitors acting prior to integration: A new mechanism of action for anti-integrase agents. J Virol 78, 5728–5736 (2004). (10.1128/JVI.78.11.5728-5736.2004) / J Virol / Styrylquinolines, integrase inhibitors acting prior to integration: A new mechanism of action for anti-integrase agents by Bonnenfant S (2004)
  39. JF Mouscadet, E Deprez, D Desmaële, J D'Angelo HIV-1 Integrase: Mechanism and Inhibitor Design, ed N Neamati (Wiley, Hoboken, NJ), pp. 325–339 (2011). (10.1002/9781118015377.ch22) / HIV-1 Integrase: Mechanism and Inhibitor Design by Mouscadet JF (2011)
  40. BA Desimmie, et al., Phage display-directed discovery of LEDGF/p75 binding cyclic peptide inhibitors of HIV replication. Mol Ther 20, 2064–2075 (2012). (10.1038/mt.2012.132) / Mol Ther / Phage display-directed discovery of LEDGF/p75 binding cyclic peptide inhibitors of HIV replication by Desimmie BA (2012)
  41. J De Rijck, et al., Overexpression of the lens epithelium-derived growth factor/p75 integrase binding domain inhibits human immunodeficiency virus replication. J Virol 80, 11498–11509 (2006). (10.1128/JVI.00801-06) / J Virol / Overexpression of the lens epithelium-derived growth factor/p75 integrase binding domain inhibits human immunodeficiency virus replication by De Rijck J (2006)
  42. A Bukovsky, H Göttlinger, Lack of integrase can markedly affect human immunodeficiency virus type 1 particle production in the presence of an active viral protease. J Virol 70, 6820–6825 (1996). (10.1128/jvi.70.10.6820-6825.1996) / J Virol / Lack of integrase can markedly affect human immunodeficiency virus type 1 particle production in the presence of an active viral protease by Bukovsky A (1996)
  43. MD Moore, et al., Suboptimal inhibition of protease activity in human immunodeficiency virus type 1: Effects on virion morphogenesis and RNA maturation. Virology 379, 152–160 (2008). (10.1016/j.virol.2008.06.030) / Virology / Suboptimal inhibition of protease activity in human immunodeficiency virus type 1: Effects on virion morphogenesis and RNA maturation by Moore MD (2008)
  44. B Taddeo, F Carlini, P Verani, A Engelman, Reversion of a human immunodeficiency virus type 1 integrase mutant at a second site restores enzyme function and virus infectivity. J Virol 70, 8277–8284 (1996). (10.1128/jvi.70.12.8277-8284.1996) / J Virol / Reversion of a human immunodeficiency virus type 1 integrase mutant at a second site restores enzyme function and virus infectivity by Taddeo B (1996)
  45. TM Jenkins, A Engelman, R Ghirlando, R Craigie, A soluble active mutant of HIV-1 integrase: Involvement of both the core and carboxyl-terminal domains in multimerization. J Biol Chem 271, 7712–7718 (1996). (10.1074/jbc.271.13.7712) / J Biol Chem / A soluble active mutant of HIV-1 integrase: Involvement of both the core and carboxyl-terminal domains in multimerization by Jenkins TM (1996)
  46. GV Kalpana, et al., Isolation and characterization of an oligomerization-negative mutant of HIV-1 integrase. Virology 259, 274–285 (1999). (10.1006/viro.1999.9767) / Virology / Isolation and characterization of an oligomerization-negative mutant of HIV-1 integrase by Kalpana GV (1999)
  47. LQ Al-Mawsawi, A Hombrouck, R Dayam, Z Debyser, N Neamati, Four-tiered pi interaction at the dimeric interface of HIV-1 integrase critical for DNA integration and viral infectivity. Virology 377, 355–363 (2008). (10.1016/j.virol.2008.04.030) / Virology / Four-tiered pi interaction at the dimeric interface of HIV-1 integrase critical for DNA integration and viral infectivity by Al-Mawsawi LQ (2008)
  48. HEV Brown, H Chen, A Engelman, Structure-based mutagenesis of the human immunodeficiency virus type 1 DNA attachment site: Effects on integration and cDNA synthesis. J Virol 73, 9011–9020 (1999). (10.1128/JVI.73.11.9011-9020.1999) / J Virol / Structure-based mutagenesis of the human immunodeficiency virus type 1 DNA attachment site: Effects on integration and cDNA synthesis by Brown HEV (1999)
  49. F Dyda, et al., Crystal structure of the catalytic domain of HIV-1 integrase: Similarity to other polynucleotidyl transferases. Science 266, 1981–1986 (1994). (10.1126/science.7801124) / Science / Crystal structure of the catalytic domain of HIV-1 integrase: Similarity to other polynucleotidyl transferases by Dyda F (1994)
  50. KK Pandey, S Bera, DP Grandgenett, The HIV-1 integrase monomer induces a specific interaction with LTR DNA for concerted integration. Biochemistry 50, 9788–9796 (2011). (10.1021/bi201247f) / Biochemistry / The HIV-1 integrase monomer induces a specific interaction with LTR DNA for concerted integration by Pandey KK (2011)
Dates
Type When
Created 12 years, 4 months ago (April 23, 2013, 3:10 a.m.)
Deposited 3 years, 2 months ago (June 7, 2022, 6:05 a.m.)
Indexed 2 weeks, 5 days ago (Aug. 7, 2025, 4:42 p.m.)
Issued 12 years, 4 months ago (April 22, 2013)
Published 12 years, 4 months ago (April 22, 2013)
Published Online 12 years, 4 months ago (April 22, 2013)
Published Print 12 years, 3 months ago (May 21, 2013)
Funders 0

None

@article{Jurado_2013, title={Allosteric integrase inhibitor potency is determined through the inhibition of HIV-1 particle maturation}, volume={110}, ISSN={1091-6490}, url={http://dx.doi.org/10.1073/pnas.1300703110}, DOI={10.1073/pnas.1300703110}, number={21}, journal={Proceedings of the National Academy of Sciences}, publisher={Proceedings of the National Academy of Sciences}, author={Jurado, Kellie A. and Wang, Hao and Slaughter, Alison and Feng, Lei and Kessl, Jacques J. and Koh, Yasuhiro and Wang, Weifeng and Ballandras-Colas, Allison and Patel, Pratiq A. and Fuchs, James R. and Kvaratskhelia, Mamuka and Engelman, Alan}, year={2013}, month=apr, pages={8690–8695} }